State Street SPDR S&P Biotech ETF (XBI)

XBI tracks a modified equal-weight biotech index across roughly 165 to 167 holdings, limiting dependence on any single company. The fund had $10.4 billion in assets under management (AUM), meaning the portfolio's total market value, and a 0.35% distribution yieldas of October 30, 2026. Biotech's clinical, earnings, and regulatory calendar remains the main exposure driver, while XBI was down 2.02% today.